tradingkey.logo

Johnson & Johnson Leads With First PARP Inhibitor Combo To Improve Efficacy In Patients With HRR-altered mCSPC

ReutersJun 3, 2025 12:57 PM

- Johnson & Johnson JNJ.N:

  • JOHNSON & JOHNSON LEADS WITH FIRST PARP INHIBITOR COMBO TO IMPROVE EFFICACY IN PATIENTS WITH HRR-ALTERED MCSPC

  • JOHNSON & JOHNSON - 50% REDUCTION IN DISEASE PROGRESSION IN BRCA-ALTERED MCSPC

  • JOHNSON & JOHNSON - PHASE 3 AMPLITUDE STUDY SHOWS AKEEGA DELAYS CANCER PROGRESSION

  • JOHNSON & JOHNSON - PHASE 3 AMPLITUDE STUDY MEETS PRIMARY ENDPOINT OF RPFS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI